

# Appendix

## Acknowledgments

### *Contributors*

The authors are deeply indebted to the following experts who provided insightful and valuable comments on the document: John Eckfeldt, University of Minnesota, Minneapolis, MN; George Eisenbarth, University of Colorado Health Sciences Center, Denver, CO; Callum Fraser, Ninewells Hospital and Medical School, Dundee, Scotland; Len Harrison, Walter and Eliza Hall Institute, Royal Melbourne Hospital, Melbourne, Australia; Ake Lernmark, University of Washington, Seattle, WA; Randie Little, University of Missouri, Columbia, MO; Kor Miedema, Ziekenhuis De Weezenlanden, JW Zwolle, The Netherlands; David Nathan, Harvard Medical School, Boston, MA; and Michael Steffes, University of Minnesota, Minneapolis, MN.

We thank the following for comments during open discussion at the AACC Annual Meeting: Jim Boyd, Robert Dufour, Steven Johnson, Gerald Kost, Matthew Meerkin, Patricia Mueller, Gary Myers, Kimberly Porter, William Roberts, and Sverre Sandberg.

We apologize if we have inadvertently omitted anyone who contributed.

### *Sponsors*

Publication of these guidelines was supported by grants from the **American Association for Clinical Chemistry** and the following:

#### **Contributing Corporate Sponsors:**

- Abbott Diagnostics
- PerkinElmer Life Sciences

#### **Participating Corporate Sponsors:**

- Beckman Coulter
- Bio-Rad Laboratories
- Diagnostic Products Corporation
- Tosoh Medics, Inc.

*On behalf of the NACB, its Officers, Board of Directors, and members, and on behalf of the editors, authors and participants in this LMPG, I would like to recognize and thank the above named companies for their generous support of this monograph and the NACB's LMPG process. I also wish to thank Dr. Edward Sasse and the NACB's Fund Raising Committee for their efforts in gathering this support.*

*Charles D. Hawker, Ph.D., FACB  
President, NACB*

## NACB Publications

NACB publications are available through AACC Press. To make a purchase or request a catalog, contact AACC Customer Service at 202-857-0717 or [custserv@aacc.org](mailto:custserv@aacc.org) or follow the information below to view AACC's online catalog.

To use the AACC online catalog, go to: <http://www.aaccdirect.org>.

Go to the catalog search and perform a search by title or series.

## **NACB Laboratory Medicine Practice Guidelines**

### **Diagnosis and Monitoring of Hepatic Injury: Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Monitoring**

Edited by D. Robert Dufour

Hepatic injury, particularly that due to viral infection, is a common problem worldwide. End-stage complications of chronic hepatic injury such as cirrhosis (the 9<sup>th</sup> leading cause of death in North America) and hepatocellular carcinoma (the 5<sup>th</sup> leading cause of cancer death world-wide) are increasing in frequency and will continue to increase over the next three decades. This monograph, developed in part in cooperation with the American Association for Liver Diseases, offers recommendations in two major areas. First, recommendations are offered to laboratories on necessary performance characteristics and reference values for chemical, virologic, and serologic tests used to recognize hepatic injury. Second, specific recommendations are provided to clinicians and laboratorians for use of tests in diagnosis and monitoring of patients with acute and chronic liver disease. The final section of the book offers recommendations on detecting cirrhosis and hepatocellular carcinoma. Over 300 references are included to provide the scientific background on which the recommendations are based.

2000, 59 pages, softcover, \$20, Product # 1174

### **Recommendations for Use of Cardiac Markers in Coronary Artery Diseases**

Edited by Alan H.B. Wu, Fred S. Apple, and Myron M. Warshaw

The practice of cardiology has undergone significant changes in recent years with development of new diagnostic and therapeutic modalities. Cardiac markers continue to play a major role in the diagnosis and management of patients with acute coronary syndromes. This monograph provides recommendations on the use of cardiac markers for rule-out of coronary artery disease of emergency department patients who present with chest pain and for the diagnosis and prognosis of patients with unstable angina and acute myocardial infarction. Also included are the criteria for establishing cutoff concentrations, assay precision, and reporting turn-around-times, and recommendations for testing cardiac markers using point-of-care testing devices.

1999, 44 pages, softcover, \$20, Product # 510

### **Guidelines for Therapeutic Drug Monitoring Services**

Edited by Ann Warner and Thomas Annesley

The many recommendations presented in this monograph are intended to provide clinical laboratory scientists with the necessary information to develop a clinically relevant, cost-effective therapeutic drug monitoring service. Nine classes of drugs are covered for clinical utility and indications for monitoring, performance goals, interferences, pre-analytic and analytic issues. This material represents an extensive compilation of information which has been reviewed by experts and a consensus style conference held in Atlanta in July 1997.

1999, 110 pages, softcover, \$20, Product #508

### **Other LMPG Titles**

#### **Guidelines for the Evaluation & Management of the Newborn Infant**

Edited by Lawrence A. Kaplan and Susan M. Tange

1998, 84 pages, softcover, \$20, Product # 501

#### **Laboratory Support for the Diagnosis & Monitoring of Thyroid Disease**

Edited by Lawrence A. Kaplan and Clark T. Sawin

1996, 64 pages, softcover, \$20, Product #509

#### **Laboratory Support in Assessing and Monitoring Nutritional Status**

Edited by Lawrence A. Kaplan

1994, 28 pages, softcover, \$20, Product # 1175

### **Other NACB Publications**

#### **Connecting the Laboratory to the Electronic Medical Record: Issues and Opportunities CD-ROM**

Edited by Jay Jones, Steven Steindel, and David Chou

2000, CD-ROM, \$39, Product # 1176